Barlaam, Bernard team published research on Journal of Medicinal Chemistry in 2015 | 38256-93-8

38256-93-8, 2-Methoxy-N-methylethanamine is a useful research compound. Its molecular formula is C4H11NO and its molecular weight is 89.14 g/mol. The purity is usually 95%.
2-Methoxy-N-methylethanamine is a drug that binds to the cannabinoid receptor CB1. It has been shown to be effective in the treatment of cardiac arrhythmia and may also be used as an anti-inflammatory drug. 2MEMEA has been shown to have pharmacokinetic properties that are different from those of other amines, which may be due to its ability to form hydrogen bonds with water molecules. 2MEMEA also has diversified effects on some types of cancer cells, including hyperproliferative and amine-dependent cancers., Name: 2-Methoxy-N-methylethanamine

Ethers feature bent C–O–C linkages. In dimethyl ether, the bond angle is 111° and C–O distances are 141 pm. 38256-93-8, formula is C4H11NO, Name is 2-Methoxy-N-methylethanamine. The barrier to rotation about the C–O bonds is low. The bonding of oxygen in ethers, alcohols, and water is similar. In the language of valence bond theory, the hybridization at oxygen is sp3. Name: 2-Methoxy-N-methylethanamine.

Barlaam, Bernard;Cosulich, Sabina;Degorce, Sebastien;Fitzek, Martina;Green, Stephen;Hancox, Urs;Lambert-van der Brempt, Christine;Lohmann, Jean-Jacques;Maudet, Mickael;Morgentin, Remy;Pasquet, Marie-Jeanne;Peru, Aurelien;Ple, Patrick;Saleh, Twana;Vautier, Michel;Walker, Mike;Ward, Lara;Warin, Nicolas research published 《 Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers》, the research content is summarized as follows. Several studies have highlighted the dependency of PTEN deficient tumors to PI3Kβ activity and specific inhibition of PI3Kδ has been shown activity against human B-cell cancers. We describe the discovery and optimization of a series of 8-(1-anilino)ethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamides as PI3Kβ/δ inhibitors, which led to the discovery of the clin. candidate 13, also known as AZD8186. On the basis of the lower lipophilicity of the chromen-4-one core compared to the previously utilized pyrido[1,2-a]pyrimid-4-one core, this series of compounds displayed high metabolic stability and suitable phys. properties for oral administration. Compound 13 showed profound pharmacodynamic modulation of p-Akt in PTEN-deficient PC3 prostate tumor bearing mice after oral administration and showed complete inhibition of tumor growth in the mouse PTEN-deficient PC3 prostate tumor xenograft model. 13 Was selected as a clin. candidate for treatment of PTEN-deficient cancers and has recently entered phase I clin. trials.

38256-93-8, 2-Methoxy-N-methylethanamine is a useful research compound. Its molecular formula is C4H11NO and its molecular weight is 89.14 g/mol. The purity is usually 95%.
2-Methoxy-N-methylethanamine is a drug that binds to the cannabinoid receptor CB1. It has been shown to be effective in the treatment of cardiac arrhythmia and may also be used as an anti-inflammatory drug. 2MEMEA has been shown to have pharmacokinetic properties that are different from those of other amines, which may be due to its ability to form hydrogen bonds with water molecules. 2MEMEA also has diversified effects on some types of cancer cells, including hyperproliferative and amine-dependent cancers., Name: 2-Methoxy-N-methylethanamine

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem